Ligand Pharmaceuticals (LGND) Long-Term Deferred Tax (2011 - 2026)

Ligand Pharmaceuticals (LGND) has 15 years of Long-Term Deferred Tax data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 1451.83% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.5 million (up 1451.83% YoY), and the FY2025 full-year result was $8.3 million, up 11490.28% from the prior year.
• Long-Term Deferred Tax rose to $8.5 million in Q1 2026, from $8.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $35.7 million in Q1 2022 to a low of $72000.0 in Q4 2024.
• A 5-year average of $10.1 million and a median of $8.4 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax plunged 99.09% in 2024 and surged 12112.82% in 2025, its largest moves.
• Tracing LGND's Long-Term Deferred Tax over 5 years: stood at $8.5 million in 2022, then sank by 97.49% to $214000.0 in 2023, then slumped by 66.36% to $72000.0 in 2024, then jumped by 11490.28% to $8.3 million in 2025, then rose by 1.53% to $8.5 million in 2026.
• Business Quant data shows LGND's Long-Term Deferred Tax at $8.5 million in Q1 2026, $8.3 million in Q4 2025, and $9.5 million in Q3 2025.